Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model.
OBJECTIVE
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is widely used to treat neutropenia during cytotoxic chemotherapy. The optimal scheduling of rhG-CSF is unknown and can hardly be tested in clinical studies due to numerous therapy parameters affecting outcome (chemotherapeutic regimen, rhG-CSF schedules, individual covariables). Motivated by biomathematical model simulations, we aim to investigate different rhG-CSF schedules in a preclinical chemotherapy mouse model.


METHODS
The time course of hematotoxicity was studied in CD-1 mice after cyclophosphamide (CP) administration. Filgrastim was applied concomitantly in a 2 x 3-factorial design of two dosing options (2 x 20 mug and 4 x 10 mug) and three timing options (directly, one, and two days after CP). Alternatively, a single dose of 40 mug pegfilgrastim was applied at the three timing options. The resulting cytopenia was compared among the schedules.


RESULTS
Dosing and timing had a significant influence on the effectiveness of filgrastim schedules whereas for pegfilgrastim the timing effect was irrelevant. The best filgrastim and pegfilgrastim schedules exhibited equivalent toxicity. Monocytes dynamics performed analogously to granulocytes. All schedules showed roughly the same lymphotoxicity.


CONCLUSIONS
We conclude that effectiveness of filgrastim application depends heavily on its scheduling during chemotherapy. There is an optimum of timing. Dose splitting is better than concentrated applications. Effectiveness of pegfilgrastim is less dependent on timing.
Scholz
Markus
M
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstrasse 16-18, 04107 Leipzig, Germany. markus.scholz@imise.uni-leipzig.de
Ackermann
Manuela
M
Emmrich
Frank
F
Loeffler
Markus
M
Kamprad
Manja
M
J Math Biol. 2005 Apr;50(4):397-439
15614553
Blood. 1992 Sep 15;80(6):1430-6
1381626
J Clin Oncol. 2003 Jul 1;21(13):2466-73
12829664
Blood. 1995 Dec 15;86(12):4437-45
8541532
Curr Med Res Opin. 2007 Sep;23(9):2283-95
17697451
Ann Intern Med. 1966 Feb;64(2):328-40
5216294
J Clin Oncol. 1997 Mar;15(3):1163-70
9060560
Exp Hematol. 2008 Jan;36(1):9-16
17949891
J Lab Clin Med. 1982 Nov;100(5):682-94
7130827
Transfusion. 2007 Jun;47(6):969-80
17524085
Blood. 1988 Mar;71(3):640-5
2449922
Exp Hematol. 1997 Dec;25(13):1313-25
9406990
Clin Cornerstone. 2006;8 Suppl 5:S19-28
17379160
J Pharmacol Exp Ther. 1989 Dec;251(3):1199-203
2481032
Br J Cancer. 1988 Jul;58(1):64-9
2458748
Exp Hematol. 1995 Dec;23(14):1497-502
8542937
Blood. 2004 Aug 1;104(3):626-33
14982884
J Natl Cancer Inst. 2001 Jan 3;93(1):31-8
11136839
Blood. 1998 Feb 1;91(3):863-9
9446646
Cancer Treat Rev. 2002 Apr;28 Suppl A:7-11
12173409
Oncol Rep. 2006 Aug;16(2):233-48
16820898
J Clin Oncol. 2000 Jul;18(13):2522-8
10893282
Cancer. 2004 Jan 15;100(2):228-37
14716755
Methods Find Exp Clin Pharmacol. 2000 Jun;22(5):275-80
11031727
Blood. 1992 Oct 15;80(8):2012-20
1382715
Clin Infect Dis. 1998 Jun;26(6):1270-8
9636845
Clin Cancer Res. 2001 Jul;7(7):2085-90
11448927
Blood. 2004 Oct 15;104(8):2323-31
15226178
Eur J Immunol. 1998 Mar;28(3):855-64
9541580
Semin Oncol. 2003 Aug;30(4 Suppl 13):3-9
14508714
Exp Hematol. 1999 Dec;27(12):1724-34
10641590
Am J Clin Oncol. 2006 Aug;29(4):361-3
16891862
Ann Oncol. 2005 Sep;16(9):1413-24
15932900
J Pharm Sci. 2004 May;93(5):1367-73
15067712
Support Care Cancer. 2006 Sep;14(9):901-9
16622653
Toxicol Sci. 1998 Sep;45(1):77-87
9848114
Cancer Res. 1991 Jul 15;51(14):3710-4
1712246
J Clin Oncol. 2005 Apr 20;23(12):2676-85
15837982
Inflamm Res. 2004 Aug;53 Suppl 2:S126-9
15338063
Exp Hematol. 1995 Nov;23(12):1319-23
7589288
Br J Cancer. 1998 Mar;77(6):884-9
9528829
Blood. 2003 Mar 1;101(5):1752-8
12393522
Am J Clin Oncol. 1997 Feb;20(1):63-8
9020291
J Cell Physiol. 1982 Aug;112(2):222-8
7119022
Pharmacol Res. 2004 Jul;50(1):55-8
15082029
J Clin Oncol. 2000 Jan;18(2):395-404
10637255
J Clin Oncol. 2001 May 15;19(10):2638-46
11352955
Radiat Res. 1999 Mar;151(3):363-7
10073675
Oncology. 2006;70(4):290-3
16899982
Ann Oncol. 2007 Apr;18 Suppl 2:ii89-91
17491063
Blood. 1994 Nov 1;84(9):2923-9
7524759
N Engl J Med. 2003 Jun 12;348(24):2386-95
12802024
Br J Haematol. 1993 Oct;85(2):254-9
7506564
J Clin Oncol. 1995 Dec;13(12):2916-23
8523055
Clin Ther. 1998 Jul-Aug;20(4):722-36
9737832
Cancer. 2006 May 15;106(10):2258-66
16575919
Cancer. 1990 Sep 15;66(6):1124-9
2205353
Crit Rev Oncol Hematol. 2003 Oct 15;48(Suppl):S39-47
14563520
Ann Oncol. 1993 Sep;4(8):651-6
7694634
Exp Hematol. 2006 Mar;34(3):382-8
16543072
Biocell. 2005 Apr;29(1):7-14
15954462
Lab Invest. 1996 Feb;74(2):384-94
8780158
Ann Oncol. 2002 Jun;13(6):903-9
12123336
J Natl Cancer Inst Monogr. 2001;(30):72-9
11773296
Leuk Lymphoma. 2003 Sep;44(9):1503-8
14565651
Br J Haematol. 2006 Mar;132(6):723-35
16487172
J Clin Oncol. 1990 Jun;8(6):963-77
2348230
Am J Hematol. 2001 Apr;66(4):245-51
11279634
Arch Intern Med. 1997 Sep 8;157(16):1825-31
9290541
Recent Results Cancer Res. 1982;81:1-222
6173905
Oncologist. 2005 Feb;10(2):138-49
15709216
Science. 1986 Apr 4;232(4746):61-5
2420009
J Natl Cancer Inst. 1998 Aug 19;90(16):1205-11
9719081
Ann Oncol. 2003 Jun;14(6):881-93
12796026
Cancer Invest. 2005;23(7):573-6
16305982
Proc Natl Acad Sci U S A. 1989 Dec;86(23):9499-503
2480603
Cancer Res. 1990 Oct 15;50(20):6615-9
1698539
Hematol J. 2000;1(3):159-71
11920185
Cell Prolif. 2003 Feb;36(1):27-34
12558658